Skip to main content
. 2020 Jun 27;12(1):87–100. doi: 10.1007/s13340-020-00447-5

Fig. 1.

Fig. 1

CV outcomes and mortality in overall trial population and Asian patients. aHR and 95% CI not calculated as < 14 patients with event. CI confidence interval, CV cardiovascular, HR hazard ratio, 3P-/4P-MACE three-point/four-point major adverse CV events